P
PCOVERY
Pcovery is a focused drug discovery company within the anti-fungal area
About PCOVERY
Pcovery was a Danish drug discovery company focused on the development of a novel class of broad-spectrum antifungal treatments for severe, life-threatening fungal infections, particularly in immunocompromised patients. A spinout from the University of Copenhagen and Aarhus University established in 2009, the company built its science on in-depth knowledge of the structure and biochemistry of fungal membrane proteins, combined with medicinal chemistry, targeting a unique fungal membrane transport system. Pcovery was backed by the Boehringer Ingelheim Venture Fund, Novo A/S (Novo Holdings), the Wellcome Trust and CAPNOVA, and secured a Wellcome Trust grant to advance its structural-biology pipeline. The company was wound down in 2016.
Source: Dealroom company dataAt a glance
- Founded
- 2009
- Headquarters
- Copenhagen, Denmark
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Wellcome Trust
Series A2 investors entered at this stage
Novo Holdings
Boehringer Ingelheim Venture Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about PCOVERY on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PCOVERY on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.